Antisense oligonucleotides targeting abhydrolase domain containing 2 block human hepatitis B virus propagation

Oligonucleotides

Volumn 21, Issue 2, 2011, Pages 77-84

  Ding, Xiaoran ^a   Yang, Jing ^a   Wang, Shengqi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABHYDROLASE DOMAIN CONTAINING 2; ANTISENSE OLIGONUCLEOTIDE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HYDROLASE; MESSENGER RNA; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG SYNTHESIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; VIRUS REPLICATION;

CELL LINE; CELL SURVIVAL; DNA, VIRAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; HYDROLASES; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 79954589589     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2011.0280     Document Type: Article

References (33)

1. 0-Terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol. Rev. 44, 175-205. (Pubitemid 11128307)
2. COHEN, J.S. (1993). Oligonucleotide therapy. In: Antisense Research and Applications. S.T. Crooke and B. Lebleu, eds. (CRC Press, Boca Raton, FL), pp. 205-221.
3. COMA, S., NOE, V., LAVARINO, C., ADAN, J., RIVAS, M., LOPEZ-MATAS, M., PAGAN, R., MITJANS, F., VILARO, S., PIULATS, J., and CIUDAD, C.J. (2004). Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides 4, 100-113. (Pubitemid 38987380)
4. DIAS, N., and STEIN, C.A. (2002). Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 1, 347-355.
5. DING, X.R., WANG, S.Q., et al. (2008). Whole genome expression profiling of Hepatitis B virus transfected cell line reveals the potential targets of anti-HBV drugs. Pharmacogenomics J. 8, 61-70.
6. 0-thiacytidine and related analogues. Proc. Natl. Acad. Sci. U. S. A. 88, 8495-8499. (Pubitemid 21915383)
7. EDGAR, A.J., and POLAK, J.M. (2002). Cloning and tissue distribution of three murine a/b hydrolase fold protein cDNAs. Biochem. Biophys. Res. Commun. 292, 617-625. (Pubitemid 34681104)
8. HE, Y.Y., WANG, S.Q., CHEN, S.H., et al. (2001). Construction and clinical application of a new fluorescent quantitative polymerase chain reaction technique for HBV detection. Chin. J. Hepatol. 9, 376-377.
9. HOLMQUIST, M. (2000). Alpha/beta-hydrolase fold enzymes: structures, functions and mechanisms. Curr. Protein Peptide Sci. 1, 209-235.
10. JIN, S., ZHAO, G,. LI, Z., NISHIMOTO, Y., ISOHAMA, Y., SHEN, J., ITO, T., TAKEYA, M., ARAKI, K., HE, P., and YAMAMURA, K. (2009). Age-related pulmonary emphysema in mice lacking alpha/beta hydrolase domain containing 2 gene. Biochem. Biophys. Res. Commun. 380, 419-424.
11. LAI, C.L., DIENSTAG, J., SCHIFF, E., LEUNG, N.W., ATKINS, M., HUNT, C., BROWN, N., WOESSNER, M., BOEHME, R., and CONDREAY, L. (2003). Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36, 687-696. (Pubitemid 36337972)
12. LAI, C.L., and YUEN, M.F. (2000). Profound suppression of hepatitis B virus replication with lamivudine. J. Med. Virol. 61, 367-373. (Pubitemid 30368540)
13. MARWICK, C. (1998). First antisense drug will treat CMV reti-nitis. JAMA 280, 871. (Pubitemid 28423898)
14. MIYATA, K., OIKE, Y., HOSHII, T., MAEKAWA, H., OGA-WA, H., SUDA, T., ARAKI, K., and YAMAMURA, K. (2005). Increase of smooth muscle cell migration and of intimal hyperplasia in mice lacking the a/b hydrolase domain containing 2 gene. Biochem. Biophys. Res. Commun. 329, 296-304. (Pubitemid 40255453)
15. NASSAL, M. (2008). Hepatitis B viruses: reverse transcription a different way. Virus Res. 134, 235-249.
16. PAPATHEODORIDIS, G.V., DIMOU, E., LARAS, A., PAPADI-MITROPOULOS, V., and HADZIYANNIS, S.J. (2002). Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatol-ogy 36, 219-226. (Pubitemid 34700781)
17. PATZEL, V., STEIDL, U., KRONENWETT, R., HAAS, R., and SCZAKIEL, G. (1999). A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Res. 27, 4328-4334. (Pubitemid 29533171)
18. RAPTI, I., DIMOU, E., MITSOULA, P., and HADZIYANNIS, S.J. (2007). Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45, 307-313. (Pubitemid 46374587)
19. REYES-DEL VALLE, J., HODGE, G., MCCHESNEY, M.B., and CATTANEO, R. (2009). Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen. J. Virol. 83, 9013-9017.
20. SCHERER, L.J., and ROSSIJ, J. (2003). Approaches for the sequence-specific knockdown of mRNA. Nat. Biotechnol. 21, 1457-1465. (Pubitemid 37522705)
21. SELLS, M.A., CHEN, M.L., and ACS, G. (1987). Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. U. S. A. 84, 1005-1009. (Pubitemid 17031557)
22. SELLS, M.A., ZELENT, A.Z., SHVARTSMAN, M., and ACS, G. (1988). Replication hepatitis B virus in HepG2 cells that produce infectious virions. J. Virol. 62, 2836-2844.
23. STIX, G. (1998). Shutting down a gene. Antisense drug wins approval. Sci. Am. 279, 46-50.
24. TURNER, M.A., YANG, X., YIN, D., KUCZERA, K., BORCH-ARDT, R.T., and HOWELL, P.L. (2000). Structure and function of S-adenosylhomocysteine hydrolase. Cell Biochem. Biophys. 33, 101-125.
25. UHLMANN, E., PEYMAN, A., RYTE, A., SCHMIDT, A., and BUDDECKE, E. (1999). Use of minimal modified antisense oligonucleotides for specific inhibition of gene expression. Methods Enzymol. 313, 268-284.
26. VEAL, G.J., AGRAWAL, S., and BYRN, R.A. (1998). Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro. Nucleic Acids Res. 26, 5670-5675. (Pubitemid 28554737)
27. WACHECK, V. (2006). Oligonucleotide therapeutics-an emerging novel class of compounds. Wien. Med. Wochenschr. 156, 481-487. (Pubitemid 44622125)
28. WAGNER, R.W., and FLANAGAN, W.M. (1997). Antisense technology and prospects for therapy of viral infections and cancer. Mol. Med. Today 3, 31-38. (Pubitemid 28091882)
29. WANG, S.Q., WANG, X.H., CHEN, S.H., et al. (2002). A new fluorescent quantitative polymerase chain reaction technique. Anal. Biochem. 309, 206-211.
30. WOOLF, T.M., MELTON, D.A., and JENNINGS, C.G. (1992). Specificity of antisense oligonucleotides in vivo. Proc. Natl. Acad. Sci. U. S. A. 89, 7305-7309.
31. YANG, J., BO, X.C., YAO, J., YANG, N.M., and WANG, S.Q. (2005). Differentially expressed cellular genes following HBV: potential targets of anti-HBV drugs? J. Viral Hepat. 12, 357-363. (Pubitemid 40961474)
32. ZHANG, Z.-D., CHENG, J., ZHANG, S.-L., et al. (2003). Cloning and characterization of a human hepatocyte protein, car-boxypeptidase N, which binds and activates core promoter of hepatitis B virus. World Chin. J. Digestol. 11, 1131-1134. (Pubitemid 37039678)
33. ZUKER, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406-3415. (Pubitemid 37442169)